Search Result
Results for "
NOT Receptor Modulator1
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-U00429
-
-
-
- HY-147105A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
(+)-LRH-1 modulator-1 is a stereoisomer of LRH-1 modulator-1. LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 has anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and reduces the inflammatory cytokines IL-1b and TNFa .
|
-
-
- HY-160540
-
-
-
- HY-161520
-
|
|
Glucocorticoid Receptor
NF-κB
|
Inflammation/Immunology
|
|
Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .
|
-
-
- HY-124803
-
|
|
GCGR
|
Metabolic Disease
|
|
GPCR modulator-1 is a negative allosteric modulator of GLP receptor. GPCR modulator-1 has the potential for type 2 diabetes research .
|
-
-
- HY-153637
-
|
|
Thyroid Hormone Receptor
|
Endocrinology
|
|
THR-β modulator-1 (compound 1a) is a potent thyroid hormone receptor β modulator. THR-β modulator-1 can be used in research of thyroid hormone receptor related disorders .
|
-
-
- HY-135671
-
|
|
Aryl Hydrocarbon Receptor
VEGFR
Estrogen Receptor/ERR
|
Endocrinology
Cancer
|
|
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .
|
-
-
- HY-153458
-
-
-
- HY-164311
-
|
|
Transmembrane Glycoprotein
|
Neurological Disease
|
|
GPR17 modulator-1 (Compound 2-046) is a modulator for G protein-coupled receptor 17 GPR17, with an IC50<10 nM for hGPR17 in CHO. GPR17 modulator-1 exhibits moderate pharmacokinetic characteristics in mice. GPR17 modulator-1 ix blood-brain barrier (BBB) permeable .
|
-
-
- HY-170437
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
MOR modulator-1 (compound 6) is a potent and selective μ opioid receptor (MOR) modulator. MOR modulator-1 exhibits improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT (6α-configuration). MOR modulator-1 links with carboxamido linker μ, δ, γ with Ki of 0.25, 41.1, 1.30 nM, respectively[1]
|
-
-
- HY-10861
-
|
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
D3/5-HT receptor modulator-1 (compound 5i) is a selective dopamine D3 receptor and 5-HT2A receptor antagonist and a partial 5-HT1A receptor agonist. D3/5-HT receptor modulator-1 shows Ki values of 4.5 nM, 11.9 nM, and 15.3 nM for dopamine D3, 5-HT2A, and 5-HT2A receptors. D3/5-HT receptor modulator-1 has a low affinity for dopamine D2 receptors, 5-HT2C receptors, and hERG channels. D3/5-HT receptor modulator-1 has an atypical antipsychotic profile .
|
-
-
- HY-147105
-
|
|
Orphan Receptor
|
Inflammation/Immunology
|
|
LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 shows anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces anti-inflammatory cytokine IL-10, and reduces inflammatory cytokine IL-1b and TNFa .
|
-
-
- HY-109572
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABAA receptor modulator-1 (9eey) is a GABAA receptor modulator that can be used in the study of central nervous system diseases .
|
-
-
- HY-147228
-
|
|
Checkpoint Kinase (Chk)
|
Inflammation/Immunology
Cancer
|
|
NR2F6 modulator-1 is a potent nuclear receptor subfamily 2, group F, member 6 (NR2F6) modulator. NR2F6 modulator-1 can be used for researching immune modulation and modulation of cancer stem cell activity .
|
-
-
- HY-152251
-
|
|
Cannabinoid Receptor
FAAH
|
Inflammation/Immunology
|
|
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .
|
-
-
- HY-145370
-
|
|
iGluR
|
Neurological Disease
|
|
GluN2B receptor modulator-1 is a selective GluN2B negative allosteric modulator with an IC50 value of 31 nM.
|
-
-
- HY-145997
-
|
|
Mas-related G-protein-coupled Receptor (MRGPR)
|
Inflammation/Immunology
|
|
MRGPRX4 modulator-1 (compound 31-2) is a potent mas-related g-protein receptor X4 (MRGPR X4) modulator, with antagonist activity of IC50 < 100 nM for MRGPR4. MRGPRX4 modulator-1 can be used for researching MRGPR X4 dependent diseases such as itch, pain, and autoimmune disorders .
|
-
-
- HY-112699
-
|
|
iGluR
|
Neurological Disease
|
|
AMPA receptor modulator-1 is a potent, orally active and selective AMPAR regulatory protein TARP γ-8 negative modulator with a pIC50 of 9.7, more selective over GluA1/γ-2 (pIC50=5) .
|
-
-
- HY-147560
-
|
|
Sigma Receptor
Opioid Receptor
|
Neurological Disease
|
|
σ1 Receptor/μ Opioid receptor modulator 1 (Compound 44) is a potent σ1 receptor antagonist and μ opioid receptor agonist with Kis of 1.86 nM and 2.1 nM, respectively.σ1 Receptor/μ Opioid receptor modulator 1 exhibits potent analgesic activity. σ1 Receptor/μ Opioid receptor modulator 1 can be used for the research of neuropathic pain .
|
-
-
- HY-W823500
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1 Receptor modulator 1 (Compound 7) is a potent GLP-1 receptor positive allosteric modulator. GLP-1 Receptor modulator 1 can be used for the research of obesity and type 2 diabetes .
|
-
-
- HY-110201
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .
|
-
-
- HY-147421
-
-
-
- HY-159826
-
-
-
- HY-159829
-
-
-
- HY-130630
-
|
|
mGluR
|
Neurological Disease
|
|
mGluR2 modulator 1 (compound 95) is a potent and BBB-penetrated mGluR2 (metabotropic glutamate receptor-2) positive allosteric modulator, with an EC50 of 0.03 μM. mGluR2 modulator 1 can be used for psychosis research .
|
-
-
- HY-159527
-
-
-
- HY-15618
-
|
M1 Receptor Modulator
|
mAChR
|
Neurological Disease
|
|
MK-7622 (M1 receptor modulator) is a muscarinic M1 receptor positive allosteric modulator .
|
-
-
- HY-154980
-
|
|
GPR52
|
Neurological Disease
|
|
GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases .
|
-
-
- HY-164774
-
-
-
- HY-U00420
-
-
-
- HY-151899
-
|
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
A3AR modulator 1 (MRS8054) is an orally active A3 adenosine receptor (A3AR) (Adenosine Receptor) positive allosteric modulator (PAM). A3AR modulator 1 greatly enhances Cl-IB-MECA-stimulated [ 35S]GTPγS binding Emax .
|
-
-
- HY-151876
-
|
|
Glucocorticoid Receptor
NF-κB
AP-1
|
Inflammation/Immunology
|
|
Glucocorticoid receptor modulator 1 is a highly potent and orally active non-steroidal selective glucocorticoid receptor modulator with an IC50 value of 9 nM and 130 nM for NF-κB and AP-1, respectively. Glucocorticoid receptor modulator 1 can effectively reduce the expression of inflammatory factors IL-6, IL-1β, TNF-α, also can relieve dermatitis in mice .
|
-
-
- HY-160416
-
-
-
- HY-21297
-
|
|
iGluR
|
Neurological Disease
|
|
3,5-Dihydroxy-2-naphthoic acid is a Naphthoic acid derivative. Naphthoic acid is a NMDA receptor allosteric modulator .
|
-
-
- HY-135441
-
|
|
mGluR
|
Inflammation/Immunology
|
|
PF-06422913 is an orally active, potent and selective metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator .
|
-
-
- HY-151963
-
|
|
PPAR
Glucocorticoid Receptor
|
Metabolic Disease
|
|
PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with Kis of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .
|
-
-
- HY-144399
-
|
|
Transmembrane Glycoprotein
|
Neurological Disease
|
|
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .
|
-
-
- HY-50162
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR120 modulator 1 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F1. GPR120 modulator 1 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .
|
-
-
- HY-79576
-
|
Oestrone methyl ether; 3-O-Methylestrone
|
Drug Intermediate
|
Cancer
|
|
Estrone 3-methyl ether (Oestrone methyl ether; 3-O-Methylestrone) is a synthetic intermediate useful for synthesis of estrogen receptor modulator .
|
-
-
- HY-170771
-
|
|
GABA Receptor
|
Neurological Disease
|
|
α5-GABAA receptor modulator 1 (Compound A-4) is a silencing allosteric modulator (SAM) specifically targeting the a5 subunit of the GABAA receptor, suitable for research into central nervous system (CNS) disorders .
|
-
-
- HY-144399A
-
|
|
Transmembrane Glycoprotein
|
Neurological Disease
|
|
CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid cell surface receptor known to regulate microglial activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in the cellular mRNA pool and can be used to study neurodegenerative diseases including Alzheimer's disease .
|
-
-
- HY-158638
-
|
|
Fluorescent Dye
|
Others
|
|
NBD-FTY720 phenoxy hydrochloride is a fluorescently-labeled analog of FTY720. FTY720 (HY-12005) is a potent sphingosine 1-phosphate (S1P) receptors modulator .
|
-
-
- HY-111763
-
-
-
- HY-146979
-
|
|
Adenosine Receptor
Carbonic Anhydrase
|
Cancer
|
|
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
|
-
-
- HY-100290
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.
|
-
-
- HY-P3355
-
|
|
iGluR
|
Neurological Disease
|
|
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
-
- HY-P3354
-
|
|
iGluR
|
Neurological Disease
|
|
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3355
-
|
|
iGluR
|
Neurological Disease
|
|
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
- HY-P3354
-
|
|
iGluR
|
Neurological Disease
|
|
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
